Pharmaceuticals Global News & Press Release Distribution

Pharmaceuticals

All
APAC

OTR Therapeutics Raises $100 Million in Series A Financing to Advance Early Innovation into Global Transformative Therapies

SHANGHAI, Dec. 4, 2025 /PRNewswire/ -- OTR Therapeutics, a biotechnology company dedicated to transforming early-stage innovations into globally impactful therapies, emerged from stealth and announced today the successful completion of a$100 million Series A financing closed in June 2025. The rou...

2025-12-05 09:00 2597

Innovent Biologics Announces Closing of Global Strategic Partnership with Takeda for Next-Generation IO and ADC Therapies

SAN FRANCISCO and SUZHOU, China, Dec. 4, 2025 /PRNewswire/ -- Innovent Biologics (HKEX: 01801) today announced that the global strategic collaboration with Takeda (TSE: 4502, NYSE: TAK) has closed and become effective following the satisfaction of all closing conditions. The collaboration, initia...

2025-12-05 07:38 2729

Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development

HMI-115 received FDA Fast Track Designation based on results from a Phase II clinical trial for endometriosis Mean dysmenorrhea pain score reduced by 42% Mean non-menstrual chronic pelvic pain score reduced by 52% Most patients maintained normal menstrual cycles No typical peri-menopausal sympt...

2025-12-04 20:08 5013

Hope Medicine Inc.'s HMI-115 Received U.S. FDA Fast Track Designation, Accelerating Global Development

HiroPharmaConsulting (R) Granted Patent for AI-enabled Reliability Assurance Method for Pharmacovigilance Systems

OSAKA, Japan, Dec. 4, 2025 /PRNewswire/ -- HiroPharmaConsulting (R) Co., Ltd. announced that it has received a patent for an innovative Good Pharmacovigilance Practice (GVP) Computerized System Validation (CSV) methodology designed to ensure the reliability of pharmacovigilance systems equipped ...

2025-12-04 14:00 1778

Nona Biosciences Appoints Dr. Hongjiang Miao as Chief AI Officer to Advance A³ Strategy and AI-Driven Drug Discovery

CAMBRIDGE, Mass., Dec. 3, 2025 /PRNewswire/ -- Nona Biosciences ("Nona" or the "Company"), a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced the appointment of Dr.Hongjiang Miao as Chief AI Offic...

2025-12-04 10:01 2619

INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

NANJING, China and GAITHERSBURG, Md., Dec. 3, 2025 /PRNewswire/ -- TransThera Sciences Nanjing, Inc. (the "TransThera") announced that Tinengotinib tablets have been included in the List of Products for Priority Review by the Center for Drug Evaluation ("CDE") of the National Medical Products Adm...

2025-12-04 09:57 1883

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

SUZHOU, China, Dec. 3, 2025 /PRNewswire/ -- On December 3, 2025 (local time in Arizona, USA), ImmVira Group ("ImmVira" or the "Company") announced a poster presentation at the 26th Annual Meeting of the Society of Urologic Oncology (SUO 2025). The presentation featured the latest interim clinical...

2025-12-04 08:00 2891

High Response in Bladder Cancer: Immvira Announced Its MVR-T3011 Latest Clinical Results in BCG-Unresponsive Bladder Cancer Patients at 2025 Annual Meeting of the Society of Urologic Oncology

ImpriMed to Present Ex Vivo Drug Sensitivity Data in Acute Myeloid Leukemia in Oral Presentation at American Society of Hematology Annual Meeting

Studies Demonstrate xCellSense® Platform's Ability to Predict Clinical Response and Enable Patient Stratification for Drug Development. PALO ALTO, Calif., Dec. 3, 2025 /PRNewswire/ -- ImpriMed

2025-12-04 01:00 1965

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

* FDA approval of OMLYCLO® (omalizumab-igec) 300 mg/2 mL solution in a single-dose prefilled syringe for subcutaneous injection expands dosing flexibility and supports tailored treatment for individual patients with certain allergic diseases * OMLYCLO® (omalizumab-igec) is the first and only ...

2025-12-03 08:43 4635

Kazia Therapeutics Announces Pricing of $50.0 Million Private Placement of Equity Securities

SYDNEY, Dec. 2, 2025 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity ...

2025-12-02 22:00 5131

Nature Communications | Insilico Medicine Presents AI-empowered Dual-Action PROTAC Targeting PKMYT1

* AI Designs a Novel RPOTAC from Scratch: Insilico's generative AI platform, Chemistry42, successfully designed a first-in-class PROTAC targeting PKMYT1 by creating an entirely new inhibitor and its complex linker, demonstrating a powerful, end-to-end approach to new modality drug discovery. ...

2025-12-02 22:00 3243

Yuyu Pharma Announces Strategic Investment in Dalan Animal Health as Part of Accelerated Global Expansion in Animal Health

SEOUL, South Korea, Dec. 2, 2025 /PRNewswire/ -- Yuyu Pharma announced today that it has completed a strategic investment in Dalan Animal Health, a U.S.-based biotechnology company advancing an innate immunity–based platform for developing vaccines for honeybees and shrimp. The investment marks a...

2025-12-02 22:00 4466

GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper

* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...

2025-12-02 13:00 2762

BioDlink Showcases Europe-China CMC Collaboration Amid Developmental Breakthrough

* Recognized as Biologics CDMO of the Year, BioDlink shares insights into the world's first approved EGFR-targeted ADC for recurrent/metastatic nasopharyngeal carcinoma * The company enables seamless Europe–China tech transfer and faster biologics development through an integrated, end-to-end...

2025-11-28 21:00 4028

Imugene and JW Therapeutics Announce a Collaboration to Advance onCARlytics and Carteyva® Combination in Solid Tumours

* Imugene and JW Therapeutics (Shanghai) Co., LTD have entered a strategic collaboration to evaluate a novel combination therapy using Imugene's onCARlytics (CF33-CD19) oncolytic virus and JW's CD19 CAR-T cell therapy, Carteyva®, in refractory solid tumors. * The collaboration includes precli...

2025-11-28 13:00 2145

Strategic Partnership | Sanyou Bio and Korea's FatiAbGen Join Forces to Expand the Global Biopharma Market

SHANGHAI, Nov. 27, 2025 /PRNewswire/ -- Sanyou Biopharmaceuticals (Shanghai) Co., Ltd. ("Sanyou Bio") andSouth Korea's FatiAbGen Co., Ltd. today jointly announced the signing of a comprehensive strategic collaboration agreement covering joint project development, exclusive representation in the K...

2025-11-27 22:00 3558

SK Biopharmaceuticals Expands Radiopharmaceutical Therapy Portfolio with Second In-licensed Candidate from Wisconsin Alumni Research Foundation

New addition strengthens SK Biopharmaceuticals' radiopharmaceutical therapy portfolio and reinforces its R&D capabilities through global partnerships and value chain integration SEOUL, South Korea, Nov. 26, 2025 /PRNewswire/ -- SK Biopharmaceuticals, CO., Ltd., a biotech company specializing in ...

2025-11-27 10:39 1970

Celltrion announces publication of post-hoc analysis of LIBERTY-CD study of ZYMFENTRA®  (infliximab-dyyb), indicating consistent efficacy across disease location, including the terminal ileum in Clinical Gastroenterology and Hepatology journal

* Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-dominant Crohn's disease (CD) * Findings support the therapeutic potential of ZYMFENTRA in addressing ...

2025-11-26 14:48 4419

Renalys Pharma Announces Positive Topline Results from Phase III Study of Sparsentan in Japanese Patients with IgA Nephropathy

– In a Phase 3 clinical study evaluating the efficacy and safety of sparsentan in Japanese patients with IgA nephropathy (N=35), the percent change from baseline in the 24-hour urine protein-to-creatinine ratio at Week 36, which was the study's primary endpoint, was -58.54%. Sparsentan was well-t...

2025-11-26 14:00 1729

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

XI'AN, China, Nov. 25, 2025 /PRNewswire/ -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co...

2025-11-25 22:41 3611

1 ... 28 29 303132 33 34 ... 164